CoChat

Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo

Open access
Song, Liujiang, Kauss, M. Ariel, Kopin, Etana, Chandra, Manasa, Ul-Hasan, Taihra, Miller, Erin, Jayandharan, Giridhara R., Rivers, Angela E., Aslanidi, George V., Ling, Chen, Li, Baozheng, Ma, Wenqin, Li, Xiaomiao, Andino, Lourdes M., Zhong, Li, Tarantal, Alice F., Yoder, Mervin C., Wong, Kamehameha K., Tan, Mengqun, Chatterjee, Saswati, Srivastava, Arun · 2013 · Cytotherapy
Cited by 80

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background Although recombinant adeno-associated virus serotype 2 (AAV2) vectors have gained attention owing to their safety and efficacy in number of Phase I/II clinical trials, their transduction efficiency in hematopoietic stem cells (HSCs) has been reported to be low. Only a handful of additional AAV serotype vectors have been evaluated, and comparative analyses of their transduction efficiency in HSCs from different species have not been performed. Methods Here, we evaluated the transduction efficiency of all available AAV serotype vectors (AAV1 through AAV10) in primary mouse, cynomolgus monkey, and human HSCs, respectively. The transduction efficiency of the optimized AAV vectors was also evaluated in human HSCs in a murine xenograft model in vivo. Results We observed that although there are only six amino acid differences between AAV1 and AAV6, AAV1, but not AAV6, transduce mouse HSCs cells well, whereas AAV6, but not AAV1, transduce human HSCs well. None of the 10 serotypes transduce cynomolgus monkey HSCs in vitro. We also evaluated the transduction efficiency of AAV6 vectors containing mutations in surface-exposed tyrosine residues, and observed that tyrosine (Y) to phenylalanine (F) point mutations in residues 445, 705, and 731, led to a significant increase in transgene expression in human HSCs in vitro and in a mouse xenograft model in vivo. Discussion These studies suggest that the tyrosine-mutant AAV6 serotype vectors are the most promising vectors for transducing human HSCs, and that it is possible to further increase the transduction efficiency of these vectors for their potential use in HSC-based gene therapy in humans.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcyt.2013.04.003

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 80

Metadata

Authors
Song, L., Kauss, M. A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G. R., Rivers, A. E., Aslanidi, G. V., Ling, C., Li, B., Ma, W., Li, X., Andino, L. M., Zhong, L., Tarantal, A. F., Yoder, M. C., Wong, K. K., Tan, M., Chatterjee, S., & Srivastava, A.
Venue
Cytotherapy
Publisher
Elsevier BV
Published
2013-08
Volume
15
Issue
8
Pages
986-998
ISSN
1465-3249 (ISSN-L)
OpenAlex
W1968067596
Cited by
80
References
5
FWCI
3.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo. https://app.cochat.ai/papers/10.1016/j.jcyt.2013.04.003
The paper
Song, L., Kauss, M. A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G. R., Rivers, A. E., Aslanidi, G. V., Ling, C., Li, B., Ma, W., Li, X., Andino, L. M., Zhong, L., Tarantal, A. F., Yoder, M. C., Wong, K. K., Tan, M., . . . Srivastava, A. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo. Cytotherapy. https://doi.org/10.1016/j.jcyt.2013.04.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.